The cost-effectiveness of the LighterLife weight management programme as an intervention for obesity in England

被引:11
作者
Lewis, L. [1 ]
Taylor, M. [1 ]
Broom, J. [2 ,3 ]
Johnston, K. L. [2 ]
机构
[1] Univ York, York Hlth Econ Consortium, Level 2 Market Sq, York YO10 5NH, N Yorkshire, England
[2] LighterLife, Cavendish House,Pkwy,Harlow Business Pk, Harlow, Essex, England
[3] Robert Gordon Univ, Ctr Obes Res & Epidemiol, Aberdeen, Scotland
关键词
Cost-effectiveness; LighterLife; obesity; VLCD;
D O I
10.1111/cob.12060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LighterLife Total is a very low calorie diet total dietary replacement weight reduction programme that provides Foodpacks, behavioural change therapy and group support appropriate for people with a body mass index of 30 kg m-2 or above. A model was built to assess the cost-effectiveness of LighterLife Total, compared with (i) no treatment, Counterweight, Weight Watchers and Slimming World, as a treatment for obesity in those with a body mass index of 30 kg m(-2) or above, and (ii) no treatment, gastric banding and gastric bypass in those with a body mass index of 40 kg m-2 or above. Change in body mass index over time was modelled, and prevalence of comorbidities (diabetes, coronary heart disease and colorectal cancer) was calculated. Costs (of intervention and treatment for comorbidities) and quality-adjusted life years were calculated. LighterLife Total was cost-effective against no treatment, Counterweight, Weight Watchers and Slimming World in the 30+ kg m(-2) group (incremental cost-effectiveness ratios: 11 pound 895, 12 pound 453, 12 pound 585 and 12 pound 233, respectively). In the 40+ kg m(-2) group, LighterLife Total was cost-effective against no treatment (incremental costeffectiveness ratio: 4356) pound, but less effective than gastric banding and bypass.
引用
收藏
页码:180 / 188
页数:9
相关论文
共 27 条
[1]   The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries [J].
Ara, R. ;
Brennan, A. .
OBESITY REVIEWS, 2007, 8 (04) :363-371
[2]   What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review [J].
Ara, R. ;
Blake, L. ;
Gray, L. ;
Hernandez, M. ;
Crowther, M. ;
Dunkley, A. ;
Warren, F. ;
Jackson, R. ;
Rees, A. ;
Stevenson, M. ;
Abrams, K. ;
Cooper, N. ;
Davies, M. ;
Khunti, K. ;
Sutton, A. .
HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (05) :1-+
[3]  
Buckroyd J, 2007, THERAPEUTIC GROUPS O
[4]  
Bultand B, 2007, TACKL OB FUT CHOIC P
[5]  
Cooper Z, 2003, COGNITIVE BEHAV TREA
[6]  
Curtis L, 2012, UNIT COSTS HLTH SOCI
[7]  
Department of Health, 2012, REF COSTS 2011 12
[8]  
DICLEMENTE CC, 2006, ADDICTION CHANGE ADD
[9]   Colon cancer prevalence and estimation of differing care needs of colon cancer patients [J].
Gatta, G ;
Capocaccia, R ;
Berrino, F ;
Ruzza, MR ;
Contiero, P .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1136-1142
[10]   PHYSICAL-ACTIVITY, OBESITY, AND RISK FOR COLON-CANCER AND ADENOMA IN MEN [J].
GIOVANNUCCI, E ;
ASCHERIO, A ;
RIMM, EB ;
COLDITZ, GA ;
STAMPFER, MJ ;
WILLETT, WC .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (05) :327-334